On January 21, 2026, a healthcare-focused private equity firm quietly acquired a 34-year-old Arizona supplement company most of the industry has never heard of.
Grant Avenue Capital announced the acquisition of 21st Century HealthCare in a 400-word press release. Financial terms weren't disclosed. The news barely registered outside M&A newsletters.
But if you know how middle-market PE actually works, that press release told you everything you needed to know about the next 3-5 years of one of the most valuable privately-held VMS brands in America.
It told you exactly how much enterprise value the new owners intend to create.
It told you the single highest-leverage operational lever they have available to create it.
And it told you why, somewhere inside that company right now, a CEO is being asked to make a decision about Amazon that most supplement executives don't even know they need to make.
Let me walk you through what they're actually solving for.
What PE sponsors are really buying
When a middle-market PE firm acquires a supplement company, they are not buying revenue.
They are not buying profit.
They are not buying the brand equity.
They are buying multiple expansion.
Here's the PE return model in one sentence: buy a company at an X multiple of EBITDA, operate it for 3-5 years, grow the EBITDA, and exit at a Y multiple where Y is higher than X. The returns compound in two places simultaneously. The EBITDA grows, AND the multiple paid on that larger EBITDA expands.
If you miss the multiple expansion piece, you miss 60-70% of the return math.
And that's where Amazon Subscribe & Save enters the boardroom conversation. Except nobody in the boardroom is talking about it that way yet.
The 10.7x number every supplement CEO should have tattooed on their desk
Capstone Partners published the benchmark number in their late-2025 Vitamins and Supplements Market Update. Average M&A multiple in the VMS sector between 2024 and YTD 2025: 10.7x EV/EBITDA. The broader consumer industry averaged 9.7x over the same period.
Let that sink in.
Every dollar of EBITDA at a VMS brand, properly run, is worth $10.70 at exit. Not next year. Not in a speculative valuation deck. In an actual transaction multiple, averaged across actual completed M&A events in 2024-2025.
So when Grant Avenue acquired 21st Century HealthCare and publicly stated they see "a compelling opportunity to build upon 21st Century's strong momentum by expanding its market reach across both e-commerce and retail channels," they told the world exactly what their exit model looks like.
Grow the EBITDA. Hit a revenue target that justifies a larger exit multiple. Sell to a bigger strategic or a larger PE fund in 3-5 years for significantly more than they paid.
Standard PE playbook.
What's not standard, and what most supplement operators still don't understand, is that not every dollar of EBITDA is worth 10.7x at exit.
Some dollars are worth more.
A lot more.
The hidden premium for recurring revenue
Flippa is a marketplace where thousands of actual digital business acquisitions happen every year. Their 2024-2025 transaction data is the cleanest public window we have into what buyers are actually paying.
Here's what their data shows:
Pure transactional e-commerce, meaning one-and-done purchase models, trades at 2.83x revenue (median) or roughly 3.98x profit at the mid-market level.
Subscription-based e-commerce, with meaningful recurring revenue, trades at 2.5x-4.0x revenue, with the top of the range reserved for brands where 80%+ of revenue is recurring and churn is well-controlled.
Pure SaaS, meaning 100% recurring, tops out at 6.13x profit multiples in the top quartile.
The delta between transactional and subscription isn't a rounding error. It's 50-100% of the multiple. A brand that moves even 30% of its revenue to recurring can often lift its blended exit multiple by 2-4 turns of EBITDA.
On a supplement brand targeting an exit in 3-5 years, at typical scale, 2-4 turns of multiple expansion is the difference between a very good exit and a career-making one.
The math worked out, publicly derivable
Let me show you what this looks like with entirely public numbers, using industry-standard comps.
Imagine a VMS brand with strong omnichannel distribution, the kind Grant Avenue just bought. Publicly available sources put 21st Century HealthCare at $750M in total revenue as of late 2025, with 500 employees and 300,000 square feet of GMP-certified manufacturing across Tempe.
Now let's think about the Amazon channel specifically.
Brick-and-mortar supplement brands of this scale, including NOW Foods, Nature Made, Nature's Bounty, and Spring Valley, typically run Amazon as 3-10% of total revenue. Some have pushed it higher. Most have not. A reasonable analyst assumption for a legacy omnichannel supplement brand's current Amazon footprint is therefore $15M-$60M per year depending on where in that range they sit.
Legacy brick-and-mortar supplement brands typically run Amazon at the LOW end of that range, because their historical strength is retail distribution, and Amazon has been treated as a channel to serve existing shoppers rather than acquire new ones.
So let's use mid-single-digit-millions-to-low-double-digits as the plausible starting point for the Amazon channel at a brand like this. The exact number doesn't matter for the math that follows.
What matters is where that number goes over the next 3-5 years.
Scenario A: Transactional Amazon growth (the default path)
The brand triples or quadruples their Amazon revenue via standard PPC expansion, brand store optimization, and listing quality improvements. Call it growth from $X to $3X over 3-5 years.
Contribution margin on incremental Amazon revenue: roughly 15% (typical for brick-and-mortar brands entering Amazon heavily, because margins are lower than DTC due to fees, but higher than wholesale due to direct pricing power).
Incremental CM on $2X of growth at 15% = $0.30X in new EBITDA contribution.
At a blended exit multiple of 10.7x (Capstone's VMS average), that $0.30X of CM is worth $3.21X in enterprise value at exit.
For any realistic value of X in the low-double-digit millions, that's a meaningful number.
Scenario B: Subscription-weighted Amazon growth (the compounding path)
Same starting point. Same $2X of revenue growth. Same 15% CM on the incremental revenue.
But here's what changes: because 30-40% of the incremental Amazon revenue is now recurring subscription revenue (via aggressive Amazon Subscribe & Save optimization), the quality of that EBITDA is different in the eyes of the exit buyer.
The buyer's analyst is not valuing this brand's EBITDA at a flat 10.7x. They are building a blended exit multiple that weights recurring EBITDA higher than transactional EBITDA, because recurring EBITDA has lower churn risk, higher forecasting accuracy, and the premium valuation data that every PE buyer has memorized.
A reasonable industry-standard blend for a brand with 30%+ recurring revenue mix on their fastest-growing channel: 12-14x on the recurring portion, 10.7x on the transactional portion. The blended multiple on the channel becomes roughly 11.5-12.5x.
That same $0.30X of CM now produces $3.60X-$3.75X in enterprise value instead of $3.21X.
The delta: $0.4X-$0.5X of pure enterprise value, created by nothing other than moving revenue from transactional to recurring.
Run that math across a growth trajectory that takes Amazon from a low-double-digit millions to a $30-50M channel over 5 years, which is a completely plausible analyst speculation for a well-run legacy brand that puts its weight into e-commerce, and you're looking at $30-80M of enterprise value creation purely from the subscription mix shift.
On a $200M top-line target at a healthy blended EBITDA margin, that's a meaningful percentage of the total exit value outcome.
That's the $80M question.
The answer is hiding inside Subscribe & Save
Most supplement companies have never done this math.
Their Amazon team is measured on total channel revenue. Their CFO is tracking EBITDA margin. Their CEO is reporting channel growth to the board.
Nobody is tracking the recurring revenue mix inside the Amazon channel as a distinct metric that has its own distinct impact on exit multiple.
And that is exactly why the opportunity exists.
When I published "Subscribe & Save Is Amazon's Loyalty Program. Most Brands Treat It Like a Coupon" earlier this week, I walked through the tactical reality of what's happening inside 90% of Amazon supplement brands right now:
- S&S enrollment rates below 10% of total orders
- Seller-funded discounts stuck at 5-10%
- Monthly churn rates equal to monthly new enrollment rates, creating what I called a "revolving door disguised as a subscription business"
- Net subscriber counts flat for months or years while management tells themselves they're growing
That article was written for the VP and Director level, the people who actually execute the S&S program.
This article is written for a different reader.
This article is written for the CEO whose PE sponsor just sat across from them at their first board meeting and said: "We need you to hit a number in three to five years. Here is the capital. Here is the team. Go grow the e-commerce channel."
If you are that CEO, reading this right now, here is what your Amazon team has probably not told you:
Your company's exit multiple is being decided by the Subscribe & Save strategy your brand manager thinks is a tactical detail.
The difference between a revolving door at 10% funded discount and a properly structured subscription moat at an aggressive funded discount is, at your scale, the difference between two dramatically different exit outcomes.
The difference between those two outcomes, at a $200M revenue brand at the typical VMS multiple, is comfortably in the eight-figure range, and depending on channel weighting and growth trajectory, potentially well into nine figures.
Why this is asymmetric and urgent
Here is the specific thing that makes this opportunity not just material but time-sensitive for PE-owned supplement brands right now.
Asymmetry 1: The recurring revenue mix is measurable at exit
When a potential buyer runs diligence on your brand in 3-5 years, one of the first things their analyst will pull is a cohort report of your Subscribe & Save program.
- Net subscriber growth month-over-month
- Average subscription length
- Churn rate by SKU
- Revenue concentration inside the recurring base
- Reliance on discount depth to maintain enrollment
That analyst will then build a DCF that explicitly separates your transactional EBITDA from your recurring EBITDA and applies different multiples to each. They do this on every deal. It's standard practice.
If your subscription base is a revolving door, acquired via shallow discounts and churning fast, the analyst will discount the recurring multiple toward the transactional multiple. The premium evaporates.
If your subscription base is a compounding asset, with deep discounts that create genuine commitment, low churn, and net subscriber growth visible in the 24-month cohort data, the analyst will expand the recurring multiple and apply it to a larger base of EBITDA.
The quality of your subscription program 12 months before your exit is what determines whether you get marked up or marked down.
Asymmetry 2: The time to build the base is now, not later
Subscription businesses compound. That's the entire point. But compounding requires time.
If a CEO starts building the subscription base in Year 4 of a 5-year hold, the exit buyer's analyst will see thin cohort data and discount the multiple premium. There simply isn't enough history to prove the recurring revenue is sticky.
If the CEO starts in Year 1, the buyer sees 48+ months of compounding cohort data, a clearly maturing base, and a forecastable growth trajectory. That brand gets the full multiple premium.
The enterprise value math strongly favors aggressive S&S investment in Year 1-2, not Year 4-5.
For any PE-owned supplement brand currently 12-24 months into its hold period: this is the window. The decisions made about S&S strategy in the next four quarters will determine the exit multiple outcome more than any single operational decision except perhaps manufacturing capacity.
Asymmetry 3: Most competitors won't do it
This is the part that makes it genuinely asymmetric.
Most legacy supplement brands are still running Amazon S&S at a 5-10% seller-funded discount. Most have no one on the team specifically accountable for S&S enrollment rate, net subscriber trend, or churn-by-SKU. Most CFOs do not have a line item in their monthly package that tracks recurring vs transactional Amazon revenue as distinct metrics.
That means the first PE-owned supplement brand in the category that treats Amazon S&S as a strategic value creation lever, rather than a tactical promotional program, gets the full multiple premium while its competitors are still optimizing PPC campaigns.
The window for first-mover advantage in this specific lever is probably 18-24 months before the category catches on. It's open now.
The uncomfortable dissonance
Here's the part that should make every PE-owned supplement CEO uncomfortable.
If you're reading this and you have a 3-5 year hold clock running, you're probably at the exact point in the hold where you're finalizing your growth plan for the next 18-24 months. Operational priorities. Investment allocations. Capital deployment.
You are likely putting significant investment behind:
- Manufacturing capacity expansion (legitimate, grows COGS leverage)
- Product line extensions (legitimate, grows SKU count and addressable market)
- Contract manufacturing growth (legitimate, grows B2B revenue)
- Retail distribution expansion (legitimate, grows channel depth)
- International market entry (legitimate, grows geographic TAM)
And you are probably treating Amazon as a channel that "we need to grow aggressively" without a specific strategic mandate around how to grow it.
Specifically: your Amazon team is probably growing the channel via the same PPC optimization, keyword expansion, and listing improvement levers that every supplement brand in the country is using. They're hitting their revenue targets. They're reporting green to the board.
And they are almost certainly producing transactional EBITDA that will get valued at the base multiple at exit, not recurring EBITDA that gets valued at the premium multiple.
The dollar they add to the Amazon P&L is worth 10.7x at exit.
The dollar they could be adding to the recurring Amazon base is worth 12-14x at exit.
Over 3-5 years of compounding growth, that difference is not a rounding error. It's a category of enterprise value that your current strategy is not even capturing as a distinct objective.
What the conversation should sound like in your next board meeting
If you're a CEO of a PE-owned supplement brand, here are the five questions that should be on the table at your next board-level strategic review:
1. What percentage of our current Amazon revenue is recurring Subscribe & Save, and what is that number's trajectory over the last 12 months?
If the answer is "under 15%, and it's been flat," you have a strategic opportunity. If the answer is "nobody on the team tracks that as a distinct metric," you have a measurement problem that needs to be fixed before you can even build the strategy.
2. What is the cohort trajectory of our S&S subscriber base? Net subscriber adds, month over month, for the last 24 months. What does the slope look like?
If the line is flat or the data doesn't exist, you are not building a subscription asset. You are running a revolving door, and your exit diligence team will figure that out in a week.
3. What is our seller-funded S&S discount rate, and when did we last test a materially deeper rate with a proper A/B methodology?
If the answer is "10% and we haven't tested otherwise," you are leaving premium valuation dollars on the table. The category's aggressive operators are testing 20-25%+ with specific hypotheses about enrollment lift and churn reduction.
4. For our 1P business on Amazon, what portion of our S&S funding is being pulled from existing co-op accrual versus funded as incremental margin compression?
If nobody on your team can answer this, you are probably leaving meaningful vendor negotiation leverage unclaimed. Amazon's vendor team will not volunteer the information that their co-op allocation is negotiable.
5. Has anyone on our finance team modeled our exit value at current recurring revenue mix versus a 30%+ recurring mix, using industry-standard blended multiples?
If the answer is "we don't think about exit valuation that way yet," ask your PE sponsor to walk you through how they are thinking about it on the board's behalf. They are almost certainly running this model quarterly even if it hasn't been shared with the operating team.
If your CFO cannot produce this model in two weeks, somebody in finance is not doing the work that is sitting in front of them.
The wrap
Grant Avenue Capital did not publicly disclose the purchase price of 21st Century HealthCare. They did not disclose their revenue targets. They did not disclose their hold period or their target exit multiple.
They didn't have to.
The industry math is public. The VMS multiple is public. The subscription premium data is public. The company's scale, brand portfolio, international footprint, and manufacturing capacity are all public.
If you stitch the public data together with the PE industry's standard return model, you get a reasonable analyst speculation about the intended outcome: a brand currently valued at X today, targeting an exit at 2-3X within 3-5 years, with the specific growth engine running through e-commerce and retail channel expansion as the board publicly stated.
And sitting inside that growth engine is the single most leveraged lever most supplement CEOs never think about as a strategic priority: the shift from transactional to recurring revenue inside the Amazon channel.
If you are 12 weeks into a new PE sponsorship and your Amazon Subscribe & Save strategy is "turned on at 10% and growing," you are not building enterprise value.
You are building a revolving door.
The difference between those two things is the difference between a good exit and a category-making one.
On the right-sized brand with the right-sized growth ambition, that's tens of millions of dollars in enterprise value. Potentially nine figures at the very top end.
Somebody on the team has to be doing this math.
Dan Matejsek is the founder of RavingFans.ai and creator of PerfectASIN. 27 years of e-commerce experience. $572M in career online revenue. He currently consults with Amazon brands on listing optimization, advertising strategy, and AI-powered growth.
Consulting inquiries: ravingfans.ai · All articles: ravingfans.ai/blog
